Alerts
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Servier’s acquisition of Edgewise’s muscular dystrophy business shows that rare neuromuscular disease is no longer a side market. The next test is whether investment becomes diagnosis, referral and access.
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
AI Mental Health Support Becomes a Governance Test
Alzheimer’s Drugs Force NICE Back Into the Value Debate
Europe Starts Treating Brain Health as System Resilience
Genomic Matching Works When the Evidence Is Strong Enough to Act
Precision Oncology Is Moving Faster Than Europe’s Access Machinery
England’s Cancer Plan Turns Personalised Care Into a National Delivery Test
Cancer Drugs Put Europe’s New HTA System to Its First Real Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.